Abstract
The ultimate goal of treating rheumatic disease is to achieve rapid suppression of inflammation, while at the same time minimizing the toxicities from rheumatic drugs. Different patients have different individual pharmacokinetics that can affect the drug level. Moreover, different factors, such as renal function, age or even different underlying diseases, can affect the drug level. Therefore, giving the same dosage of drugs to different patients may result in different drug levels. This article will review the usefulness of therapeutic drug monitoring in maximizing drug efficacy, while reducing the risk of toxicities in Hydroxychloroquine, Mycophenolate Mofetil, Tacrolimus and Tumor Necrosis Factor inhibitors (TNF Inhibitors).
Cite
CITATION STYLE
NG Hoi-Yan, A., & Mok, C. C. (2016). Therapeutic Drug Monitoring in Rheumatic Diseases. Hong Kong Bulletin on Rheumatic Diseases, 16(2), 33–37. https://doi.org/10.1515/hkbrd-2016-0009
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.